Bullish short-squeeze thesis on LifeVantage (LFVN) citing high short interest, costly borrow, a $60M buyback, and a profitable debt-free dividend-paying business.
LFVN — LONG The author argues LifeVantage is a profitable, debt-free, dividend-paying supplement company with $195M revenue and 78% gross margins trading at a $100M market cap, making it a fundamentally sound squeeze candidate. The mechanism is a short squeeze: 36% of float sold short, 263% annualized borrow cost, zero shares available to borrow, and 3.59M shares needing to cover into a float with only 2-3M shares available, compounded by a $60M buyback. The catalyst is continued short covering after shorts failed to break $8 by dumping 2.54M shares, with the author's stated risk being that the squeeze fails and the stock falls to $6 fair value. The author holds shares, not options, citing expensive options and uncertain timeline.
36% of float sold short
263% annualised cost for hedgies to borrow
Zero shares available to borrow anywhere
Shorts bleeding $250K every single day
3.59M shares need to cover into a float with maybe 2–3M shares actually available.
This Reddit post, published June 03, 2026, features u/RepresentativeArtist discussing LFVN. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/RepresentativeArtist · Tickers: LFVN